Oncoscience AG receives EU orphan drug status for the EGFR monoclonal antibody Nimotuzumab (Theraloc®) for the treatment of pancreatic cancer.
Oncoscience | April 22nd, 2008
Oncoscience AG announced that their anti-cancer drug Nimotuzumab (Theraloc®) has been designated an orphan drug by the ...
The European Medicines Agency, EMEA, concludes its formal validation of the marketing authorization application for Theraloc® (Nimotuzumab) positively
Oncoscience | October 26th, 2007
The application for marketing authorization of Theraloc® (Nimotuzumab) was submitted to EMEA on October 4th, 2007. Aft...
Oncoscience | October 13th, 2007
On October 12th, 2007 Theraloc® was approved in the Ukraine by the Ministry of Health of Ukraine. As of now Theraloc®...
Oncoscience AG announces completion of patient enrollment in phase III trial of NIMOTUZUMAB, in first line treatment of children with inoperable brain cancer
Oncoscience | September 12th, 2007
Clearance Received for Two Additional Late-Stage Trials in Adult Glioma and Pancreatic Cancer Today Oncoscience AG (Wed...
Oncoscience AG announces final results of a phase-II study in pediatric patients with recurrent high-grade malignant glioma treated with the monoclonal antibody NIMOTUZUMAB directed against EGF-R, as monotherapy
Oncoscience | June 8th, 2007
Final results of the Phase II trial were described in an oral presentation at the Annual Meeting of the American Society...